Heritage Investors Management Corp Sells 13,018 Shares of Teva Pharmaceutical Industries Limited (TEVA)

Heritage Investors Management Corp reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 193,668 shares of the company’s stock after selling 13,018 shares during the quarter. Heritage Investors Management Corp’s holdings in Teva Pharmaceutical Industries Limited were worth $3,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in TEVA. American International Group Inc. purchased a new stake in Teva Pharmaceutical Industries Limited in the first quarter worth $523,000. Teachers Advisors LLC increased its position in Teva Pharmaceutical Industries Limited by 6.1% in the first quarter. Teachers Advisors LLC now owns 642,314 shares of the company’s stock worth $20,612,000 after buying an additional 36,900 shares during the last quarter. State Street Corp increased its position in Teva Pharmaceutical Industries Limited by 15.9% in the first quarter. State Street Corp now owns 4,530,768 shares of the company’s stock worth $145,390,000 after buying an additional 621,795 shares during the last quarter. Bank of Nova Scotia purchased a new stake in Teva Pharmaceutical Industries Limited in the first quarter worth $391,000. Finally, M Holdings Securities Inc. increased its position in Teva Pharmaceutical Industries Limited by 36.2% in the first quarter. M Holdings Securities Inc. now owns 18,454 shares of the company’s stock worth $592,000 after buying an additional 4,902 shares during the last quarter. 56.55% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Heritage Investors Management Corp Sells 13,018 Shares of Teva Pharmaceutical Industries Limited (TEVA)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2017/11/01/heritage-investors-management-corp-sells-13018-shares-of-teva-pharmaceutical-industries-limited-teva.html.

A number of analysts have issued reports on the company. Mizuho reissued a “hold” rating and issued a $15.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Monday. Royal Bank Of Canada reissued an “underperform” rating and issued a $13.00 target price (down from $15.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday. Cantor Fitzgerald set a $17.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, October 26th. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, Barclays PLC set a $19.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Friday, October 20th. Five investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $27.83.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 0.833% during midday trading on Wednesday, reaching $13.915. The company’s stock had a trading volume of 9,010,960 shares. Teva Pharmaceutical Industries Limited has a 12 month low of $13.26 and a 12 month high of $44.13. The company’s 50-day moving average price is $16.13 and its 200-day moving average price is $24.54. The company’s market cap is $14.14 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.25 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.19 EPS for the current fiscal year.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit